Oracle Health Sciences Applications是美国甲骨文(Oracle)公司的一套用于医疗保健行业的临床研发解决方案。 Oracle Health Sciences Applications 的 Oracle Health Sciences Sciences Data Management Workbench product 存在安全漏洞,该漏洞源于 Blinding Functionality 模块允许通过 HTTP 进行网络访问的低权限攻击者破坏 Oracle Health
Although we use advanced large model technology, its output may still contain inaccurate or outdated information.Shenlong tries to ensure data accuracy, but please verify and judge based on the actual situation.
| Vendor | Product | Affected Versions | CPE | Subscribe |
|---|---|---|---|---|
| Oracle Corporation | Life Sciences Data Management Workbench | 3.1.0.2 | - |
|
| # | POC Description | Source Link | Shenlong Link |
|---|
No public POC found.
Login to generate AI POC| CVE-2023-21974 | 9.0 CRITICAL | Oracle Application Express 安全漏洞 |
| CVE-2023-21975 | 9.0 CRITICAL | Oracle Application Express 安全漏洞 |
| CVE-2023-22062 | 8.5 HIGH | Oracle Hyperion 安全漏洞 |
| CVE-2023-22014 | 8.4 HIGH | Oracle PeopleSoft Enterprise PeopleTools 安全漏洞 |
| CVE-2023-22018 | 8.1 HIGH | Oracle Virtualization 安全漏洞 |
| CVE-2023-22023 | 7.8 HIGH | Oracle Solaris 安全漏洞 |
| CVE-2023-22060 | 7.6 HIGH | Oracle Hyperion 安全漏洞 |
| CVE-2023-22047 | 7.5 HIGH | Oracle PeopleSoft Enterprise PeopleTools 安全漏洞 |
| CVE-2023-21994 | 6.5 MEDIUM | Oracle Fusion Middleware 安全漏洞 |
| CVE-2023-22040 | 6.5 MEDIUM | Oracle Fusion Middleware 安全漏洞 |
| CVE-2023-22037 | 6.5 MEDIUM | Oracle E-Business Suite 安全漏洞 |
| CVE-2023-22035 | 6.1 MEDIUM | Oracle E-Business Suite 跨站脚本漏洞 |
| CVE-2023-22042 | 6.1 MEDIUM | Oracle E-Business Suite 安全漏洞 |
| CVE-2023-22055 | 6.1 MEDIUM | Oracle JD Edwards 安全漏洞 |
| CVE-2023-21961 | 6.0 MEDIUM | Oracle Essbase 安全漏洞 |
| CVE-2023-22053 | 5.9 MEDIUM | Oracle MySQL 安全漏洞 |
| CVE-2023-22043 | 5.9 MEDIUM | Oracle Java SE 安全漏洞 |
| CVE-2023-21983 | 5.6 MEDIUM | Oracle Application Express 安全漏洞 |
| CVE-2023-22017 | 5.5 MEDIUM | Oracle Virtualization 安全漏洞 |
| CVE-2023-22020 | 5.4 MEDIUM | Oracle Business Intelligence Enterprise Edition 安全漏洞 |
Showing top 20 of 56 CVEs. View all on vendor page → →
No comments yet